GO
| HSI1 | 23,508.17 | 0.00 | -- |
| HSCEI1 | 7,904.37 | 0.00 | -- |
| Back Zoom + Zoom - Block Traded | |
|
2026-11-17 10:58:12 CMBI issued a report saying that the 2026 National Reimbursement Drug List (NRDL) and Commercial Health Insurance Innovative Drug Catalogue were released, continuing to support innovative drugs. The broker maintained its Outperform rating on China's pharmaceutical sector. The MSCI China Healthcare Index has grossed a gain of 14.8% YTD in 2026, outperforming the MSCI China Index by 32%. The scale of overseas BD transactions for innovative drugs has grown rapidly. According to the National Medical Products Administration (NMPA), the total value of outbound licensing transactions for Chinese innovative drugs reached approximately USD130 billion in the first three quarters of this year, close to the full-year 2025 level. The broker said this catalogue adjustment added 107 drugs, of which 51 were Class 1 innovative drugs, marking a record high, while 34 drugs were removed. The focus was on including innovative drugs with clear clinical benefits and strong economic evaluation results. The commercial insurance innovative drug catalogue added 12 innovative drugs, including gene therapy, CAR-T therapies for solid tumors and radiopharmaceuticals. Key innovative products from multiple companies were included, including mazdutide and picankibart from INNOVENT BIO (01801.HK), trastuzumab botidotin and sacituzumab-related indications from SKB BIO (06990.HK), trastuzumab rilkidotin and dalpiciclib-related indications from HENGRUI PHARMA (01276.HK), and the prefilled syringe version of telitacicept from REMEGEN (09995.HK). The broker recommended Buy ratings on APPTEC (603259.SH), WUXI BIO (02269.HK), DUALITYBIO-B (09606.HK), 3SBIO (01530.HK) and INNOVENT BIO, with target prices of RMB190, HKD60, HKD284.5, HKD34.78 and HKD138.63 respectively. ~ AASTOCKS Financial News Website: www.aastocks.com | |